Drugs / GIRIPLADIB
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00440492 | Dec 2006 → Nov 2007 | rheumatoid arthritis | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00366262 | Jun 2006 → Mar 2007 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00396955 | Nov 2006 → Nov 2007 | osteoarthritis, knee | Wyeth is now a wholly owned subsidiary of Pfizer | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GIRIPLADIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL2104969 ↗ |
| Known as | PLA-695 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00396955 ↗ |
| Action | Inhibit | “Cytosolic phospholipase A2 inhibitor” CHEMBL2104969 ↗ |
| Modality | Small molecule | — CHEMBL2104969 ↗ |
| Route | Oral | “3 oral doses of PLA-695 administered QD” NCT00396955 ↗ |
| Target | PLA2G4A | “Cytosolic phospholipase A2 inhibitor” CHEMBL2104969 ↗ |